Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. September 2022 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
11. August 2022 16:02 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
01. Juli 2022 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
12. Mai 2022 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update

HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
02. Mai 2022 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
24. März 2022 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed...
26. Januar 2022 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
13. Dezember 2021 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has...
06. Dezember 2021 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market

- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in...
04. November 2021 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...

Vorherige Seite

Nächste Seite